Merck discontinues late-stage trial of experimental lung cancer treatment after high number of adverse events

Merck & Co. said Thursday it’s discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events.

Previous post Eyewear seller Warby Parker narrows net loss as revenue jumps
Next post Under Armour stock climbs on Q1 top and bottom-line beat, raised outlook